Acute changes of pro-inflammatory markers and corticosterone in experimental subarachnoid haemorrhage: A prerequisite for severity assessment.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
03
2019
accepted:
16
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
11
3
2020
Statut:
epublish
Résumé
Many details of the pathophysiology of subarachnoid haemorrhage (SAH) still remain unknown, making animal experiments an indispensable tool for assessment of diagnostics and therapy. For animal protection and project authorization, one needs objective measures to evaluate the severity and burden in each model. Corticosterone is described as a sensitive stress parameter reflecting the acute burden, and inflammatory markers can be used for assessment of the extent of the brain lesion. However, the brain lesion itself may activate the hypothalamic-pituitary-adrenal-axis early after SAH, as shown for ischemic stroke, probably interfering with early inflammatory processes, thus complicating the assessment of severity and burden on the basis of corticosterone and inflammation. To assess the suitability of these markers in SAH, we evaluated the courses of corticosterone, IL-6 and TNF-α up to 6h in an acute model simulating SAH in continuously anaesthetized rats, lacking the pain and stress induced impact on these parameters. Animals were randomly allocated to sham or SAH. SAH was induced by cisterna magna blood-injection, and intracranial pressure and cerebral blood flow were measured under continuous isoflurane/fentanyl anaesthesia. Withdrawn at predetermined time points, blood was analysed by commercial ELISA kits. After 6h the brain was removed for western blot analysis of IL-6 and TNF-α. Serum corticosterone levels were low with no significant difference between sham and SAH. No activation of the HPA-axis was detectable, rendering corticosterone a potentially useful parameter for stress assessment in future chronic studies. Blood IL-6 and TNF-α increased in both groups over time, with IL-6 increasing significantly more in SAH compared to sham towards the end of the observation period. In the basal cortex, IL-6 and TNF-α increased only in SAH. The pro-inflammatory response seems to start locally in the brain, reflected by an increase in peripheral blood. An additional surgery-induced systemic inflammatory response should be considered.
Identifiants
pubmed: 31361786
doi: 10.1371/journal.pone.0220467
pii: PONE-D-19-08052
pmc: PMC6667150
doi:
Substances chimiques
Inflammation Mediators
0
Corticosterone
W980KJ009P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220467Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Cereb Blood Flow Metab. 1999 Nov;19(11):1256-62
pubmed: 10566972
J Cereb Blood Flow Metab. 2000 Jan;20(1):53-65
pubmed: 10616793
Neurosurgery. 2000 Feb;46(2):448-60; discussion 460-1
pubmed: 10690735
J Neurosurg Anesthesiol. 2000 Oct;12(4):297-306
pubmed: 11147377
J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):534-7
pubmed: 11254783
Can J Physiol Pharmacol. 1975 Aug;53(4):629-37
pubmed: 1175088
J Trauma. 2002 Feb;52(2):339-45
pubmed: 11834998
J Exp Med. 2003 Sep 1;198(5):725-36
pubmed: 12939340
BMC Neurol. 2004 Jan 15;4:2
pubmed: 14725719
Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):141-7
pubmed: 15159698
J Endocrinol. 2005 Jan;184(1):153-63
pubmed: 15642792
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E823-8
pubmed: 15956051
Nat Rev Neurosci. 2005 Oct;6(10):775-86
pubmed: 16163382
Endocrine. 2005 Dec;28(3):325-32
pubmed: 16388123
J Cereb Blood Flow Metab. 2006 Nov;26(11):1341-53
pubmed: 16482081
Neurosurgery. 2007 May;60(5):828-36; discussion 828-36
pubmed: 17460517
Endocrinology. 2008 Jul;149(7):3244-53
pubmed: 18356272
Anesth Analg. 2009 Jan;108(1):288-95
pubmed: 19095864
Mol Neurobiol. 2011 Feb;43(1):27-40
pubmed: 21161614
Br J Neurosurg. 2011 Dec;25(6):684-92
pubmed: 22115015
Nat Rev Neurosci. 2013 May;14(5):365-76
pubmed: 23571845
Stroke Res Treat. 2013;2013:615154
pubmed: 23878760
Horm Behav. 2014 Mar;65(3):273-84
pubmed: 24444675
Lab Anim. 2014 Feb 4;48(3):178-192
pubmed: 24496575
Brain Behav Immun. 2014 Oct;41:200-9
pubmed: 24886966
PLoS One. 2015 Apr 13;10(4):e0123398
pubmed: 25867893
Drug Des Devel Ther. 2015 Jul 02;9:3445-54
pubmed: 26170628
Clin Neurol Neurosurg. 2015 Nov;138:177-83
pubmed: 26355810
J Clin Neurophysiol. 2016 Jun;33(3):174-82
pubmed: 27258440
Circ Res. 2017 Feb 3;120(3):439-448
pubmed: 28154096
Transl Stroke Res. 2018 Jun;9(3):284-293
pubmed: 29119370
Transl Stroke Res. 2018 Jun 20;:null
pubmed: 29926382
Neuroscience. 1996 Mar;71(1):1-16
pubmed: 8834388
J Neurosurg. 1997 Aug;87(2):215-20
pubmed: 9254084
Neurology. 1998 May;50(5):1413-8
pubmed: 9595997
Neurol Res. 1998 Jun;20(4):337-42
pubmed: 9618698
Acta Neurochir (Wien). 1998;140(9):943-51
pubmed: 9842432